| Literature DB >> 27654928 |
Rimda Wanchoo1, Ala Abudayyeh2, Mona Doshi3, Amaka Edeani4, Ilya G Glezerman5, Divya Monga6, Mitchell Rosner7, Kenar D Jhaveri8.
Abstract
Survival for patients with multiple myeloma has significantly improved in the last decade in large part due to the development of proteasome inhibitors and immunomodulatory drugs. These next generation agents with novel mechanisms of action as well as targeted therapies are being used both in the preclinical and clinical settings for patients with myeloma. These agents include monoclonal antibodies, deacetylase inhibitors, kinase inhibitors, agents affecting various signaling pathways, immune check point inhibitors, and other targeted therapies. In some cases, off target effects of these therapies can lead to unanticipated effects on the kidney that can range from electrolyte disorders to AKI. In this review, we discuss the nephrotoxicities of novel agents currently in practice as well as in development for the treatment of myeloma.Entities:
Keywords: Acute Kidney Injury; Antibodies, Monoclonal; Coal Tar; Proteasome Inhibitors; Water-Electrolyte Imbalance; acute renal failure; cancer; chronic kidney disease; drug nephrotoxicity; electrolytes; humans; kidney; multiple myeloma
Mesh：
Substances：
Year: 2016 PMID： 27654928 PMCID： PMC5220662 DOI： 10.2215/CJN.06100616
Source DB: PubMed Journal: Clin J Am Soc Nephrol ISSN： 1555-9041 Impact factor: 8.237